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The use of antibiotic combinations is garnering increased interest in the recent years 
due to the spread of antibiotic-resistant bacteria. The shortage of antibacterial therapy 
options is particularly severe for infections caused by Gram-negative bacteria, due to 
the formidable barrier to molecules > 600 Da imposed by the outer membrane. 
Vancomycin is a large glycopeptide antibiotic to which the outer membrane is poorly 
permeable, hence the minimal inhibitory concentration of this antibiotic for Escherichia 
coli is very high (~500 mg/L). Due to the resistance of E. coli and other Gram-negative 
pathogens to an increasing number of < 600 Da antibiotics including beta lactams, 
aminoglycosides and quinolones, enabling vancomycin use on Gram-negative bacteria 
would be valuable. Furazolidone was reported to increase sensitivity of E. coli to 
vancomycin, and this interaction has been investigated in this thesis in order to explore 
the potential of the vancomycin-furazolidone combination for clinical applications. The 
initial analysis of the vancomycin-furazolidone synergy demonstrated that their 
interaction is synergistic rather than merely additive. Furthermore, effectiveness of this 
combination for growth inhibition and eradication of E. coli biofilm was investigated. 
However, despite the synergy between vancomycin and furazolidone, the concentration 
of vancomycin in combinations required for growth inhibition and killing of E. coli in a 
planktonic mode and as a biofilm was above the nephrotoxicity (toxicity in the kidneys) 
threshold and therefore too high to treat infections with this organism systemically. 
However, by adding deoxycholic acid to the combination, the bactericidal vancomycin 
concentration was decreased below the nephrotoxicity threshold. The mechanism of 
synergy in the planktonic mode of growth was investigated through the analysis of E. 
coli gene-knock-out mutants and it was observed that TolC, the outer membrane 
channel common to a number of efflux systems (exporting enterobactin, xenobiotics 
and metabolites) is likely to be involved in vancomycin-furazolidone synergy. 
However, it was not possible to reliably pinpoint any particular efflux pump or 
enterobactin accumulation as factors in synergy. Using the genetic approach, it was 
found that DNA excision repair endonuclease UvrABC was ruled out as a factor 
involved in synergy. Overall this study characterised the synergy between vancomycin 
and furazolidone, initiated the enquiry into the mechanisms of interaction between 
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%   Percentage 
$   Dollars 
°C   Degrees Celsius 
μL   Microlitre 
μm   Micrometre 
8-OHdG  8-hydroxydeoxyguanosine 
ABC   Adenosine triphosphate binding cassette 
AMR   Antimicrobial resistance 
ATP   Adenosine triphosphate 
CaCl2   Calcium chloride 
CAUTI  Catheter associated infections 
CDC   Centres for Disease Control and Prevention 
CFU/mL  Colony forming units per millilitre 
Da   Daltons 
DMSO   Dimethyl sulfoxide 
DNA   Deoxyribonucleic acid 
DOC   Sodium deoxycholate 
ECM   Extracellular matrix 
ESBL   Extended-spectrum beta-lactamase 
FICI   Fractional Inhibitory Concentration Index 
g   Grams 
g/L   Grams per litre 




kDa   Kilodaltons 
KmR   Kanamycin resistance marker 
kPa   Kilopascals 
LPS   Lipopolysaccharide 
MATE   Multidrug and toxic efflux 
MBC   Minimal Bactericidal Concentration  
MBEC   Minimal Biofilm Eradication Concentration 
MBIC   Minimal Biofilm Inhibitory Concentration 
mg/kg   Milligram per kilogram 
mg/kg/day  Milligram per kilogram per day 
mg/L   Milligram per litre 
MgSo4   Magnesium sulfate 
MIC   Minimal Inhibitory Concentration 
mL   Millilitre 
mM   Millimolar 
MRSA   Methicillin resistant S. aureus 
Na   Sodium 
nm   Nanometre 
NO   Nitric oxide 
NZ   New Zealand 
OD   Optical density 
ORF   Open reading frame 
PMF   Proton motive force 




Rpm   Revolutions per minute 
ROS   Reactive oxygen species 
SOC   Super Optimal broth with Catabolite repression 
SMR   Small multidrug resistance 
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